secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0000950170-25-071399
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025
--------------------------------------------------------------------------------

- Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.
- March 2025 restructuring cut 34% workforce; cash runway extended beyond 2029.
- Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen updated.
- Initial NKX019 data across autoimmune indications expected H2 2025; both ISTs open.
- Robert Ortmann, M.D. appointed VP Clinical Development, joining May 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/0000950170-25-071399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017025071399/nktx-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-071399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer